Bolli et al. found no significant survival difference between cases with and without KRAS, NRAS or BRAF mutations [4], whereas Andrulis et al. [7] found that overall survival was significantly shorter in their MM patients carrying BRAF V600E. This evidence concerns the gene BRAF and Miyoshi myopathy.